CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/12 (2013.01); A61K 31/192 (2013.01); A61K 31/4436 (2013.01); A61K 45/06 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] | 17 Claims |
1. A topical pharmaceutical composition for treating psoriasis, the composition comprising:
(a) halobetasol propionate at a concentration of about 0.01% by weight of the composition;
(b) tazarotene at a concentration of about 0.045% by weight of the composition; and
(c) a dermatologically acceptable carrier comprising:
diethyl sebacate at a concentration of about 2.5% to 3.5% by weight of the composition, a mineral oil at a concentration of about 7.5% to 8.5% by weight of the composition, carbomer copolymer type B at a concentration of about 0.3% to 0.5% by weight of the composition,
carbomer homopolymer type A at a concentration of about 0.5% to about 0.7% by weight of the composition, and
purified water.
|